Therefore targeting CDH2 improved the efficacy of TIL-related treatment by decreasing PDL-1 and IDO-1, and indeed ADH-1 with TIL-treatment reduced tumour size and increased survival in the mouse models (Ref. The gene discussed is ADH1A; the disease is neoplasm.